Form 4: Twist Bioscience CEO Sells Shares to Cover Tax Obligations from RSU Vesting
Insider Transaction Report
Twist Bioscience Corporation's CEO, Emily M. Leproust, reported a non-discretionary sale of 1,678 common shares to satisfy tax withholding obligations related to vested Restricted Stock Units.
Summary
- Emily M. Leproust, Chief Executive Officer and Director of Twist Bioscience Corp. (TWST), reported a transaction on June 20, 2025.
- The transaction involved the sale of 1,678 shares of common stock at a price of $35.755 per share.
- This sale was explicitly stated as a 'sell to cover' transaction, mandated by the Issuer's equity incentive plans to cover tax withholding obligations associated with the vesting of Restricted Stock Units.
- The sale was not a discretionary trade by the Reporting Person.
- Following this transaction, Ms. Leproust beneficially owns 645,782 shares of common stock directly.
- The filing also details various employee stock options held by Ms. Leproust, with exercise prices ranging from $5.95 to $67.85 and expiration dates extending to August 31, 2030.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the transaction is a non-discretionary 'sell to cover' for tax purposes, which is a routine event and does not reflect a discretionary decision by the CEO regarding the company's stock value.
Positives
- The sale of shares was non-discretionary, indicating it was not a reflection of management's lack of confidence in the company's future prospects but rather a standard tax compliance procedure.
- The CEO retains a substantial beneficial ownership of 645,782 shares after the transaction, demonstrating continued alignment with shareholder interests.
Negatives
- A reduction in the CEO's direct shareholding, even if for tax purposes, represents a slight decrease in direct ownership.
Future Outlook
This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic outlook.
Industry Context
This filing is a routine insider transaction report, common for executives of publicly traded companies when Restricted Stock Units (RSUs) vest. It does not provide insights into broader industry trends or competitive dynamics within the synthetic biology or genomics sector.
Stakeholder Impact
- Shareholders: Minimal direct impact as the sale is small and non-discretionary, not signaling a change in management's confidence.
- Employees: No direct impact mentioned.
- Customers: No direct impact mentioned.
- Suppliers: No direct impact mentioned.
- Creditors: No direct impact mentioned.
Key Dates
| Date | Description |
|---|---|
| 09/01/2016 | Vesting start date for an employee stock option (25% vested, then 1/48th monthly). |
| 09/28/2017 | Vesting start date for an employee stock option (10% vested). |
| 09/28/2018 | Vesting date for an employee stock option (additional 15% vested). |
| 10/31/2019 | Vesting start date for an employee stock option (20% vested, then 1/60th monthly). |
| 09/01/2020 | Grant date for performance stock options. |
| 10/24/2020 | Vesting start date for an employee stock option (25% vested, then 1/48th monthly). |
| 12/19/2022 | Performance stock options vested and became exercisable due to performance criteria being met. |
| 06/20/2025 | Date of common stock transaction (sale of shares). |
| 06/24/2025 | Date the Form 4 was signed and filed. |
| 09/28/2025 | Expiration date for an employee stock option with an exercise price of $5.95. |
| 09/28/2027 | Expiration date for an employee stock option with an exercise price of $8.82. |
| 11/18/2028 | Expiration date for an employee stock option with an exercise price of $26.66. |
| 10/23/2029 | Expiration date for an employee stock option with an exercise price of $23.33. |
| 08/31/2030 | Expiration date for an employee stock option with an exercise price of $67.85. |
Keywords
SEC Form 4, Insider Trading, Stock Sale, Twist Bioscience, TWST, Emily M. Leproust, CEO, Restricted Stock Units, Tax Withholding, Sell to Cover, Equity Incentive Plans
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.